Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2019032877) MICELLES AND VESICLES FOR THE DELIVERY OF GLYCOPEPTIDES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A method of optimizing formation of a g!ycoaggregate, the method comprising: a. forming a first giycoaggregate from at least two co-surfactants according to two or more reaction parameters, wherein the at least two co-surfactants comprises a glycopeptide and a lipid;

b. characterizing the first giycoaggregate using Diffusion Ordered Spectroscopy (DOSY) to determine a first diffusion coefficient; c. modifying at least one of the reaction parameters;

d. forming a second giycoaggregate from at least two co-surfactants according to the modified reaction parameters, wherein the at least two co- surfactants comprises a glycopeptide and a lipid;

e. characterizing the second giycoaggregate using DOSY to determine a second diffusion coefficient; and

f. comparing the first and second diffusion coefficients to determine if the first giycoaggregate or the second giycoaggregate is more suitable for a specific application.

2. The method of claim 1 , wherein the first giycoaggregate is a micelle or vesicle.

3. The method of claim 1 , wherein the second giycoaggregate is a micelle or vesicle.

4. The method of claim 1 , wherein the reaction parameters are selected from the group comprising a number of the co-surfactants, a selection of the co- surfactants, a ratio of the co-surfactants, a concentration of the co-surfactants, an order of addition of the co-surfactants, a reaction temperature, a mixing time, a presence of a catalyst, and a type of solvent system.

5. The method of claim 1 , wherein the glycopeptide is a drug or a pro-drug.

6. The method of claim 1 , wherein the glycopeptide is synthesized by providing a peptide, providing a saccharide, and covalently linking the peptide with the saccharide, thereby forming said glycopeptide.

7. The method of claim 6, wherein the peptide includes a serine residue, wherein the saccharide is linked to the serine residue.

8. The method of claim 6, wherein the saccharide is a glucose.

9. The method of claim 6, wherein the peptide is a drug or a pro-drug.

10. The method of claim 1 , wherein the glycopeptide is a glycosylated opioid peptide.

1 1. The method of claim 1 , wherein the glycopeptide is lactomorphin.

12, The method of claim 1 , wherein the specific application is drug delivery,

13, The method of claim 1 , wherein the lipid is a glycolipid according to any one of the following structures:


wherein R; is H, OH, Ο-β-D-Glucose, Ο-β-D-Galactose, or O-a-D-Glucose wherein R2 is H or OH;

wherein the chain is accordin to any one of the following formulas:


wherien n is 6, 8, or 10.

14. The method of claim 1 , wherein the lipid is according to any one of the following structures:

,30° Na®


15. A method of quality control for the formation of a glycoaggregate, the method comprising:

a. forming the glycoaggregate from at least two co-surfactants, wherein the first co-surfactant comprises a glycopeptide and the second co-surfactant comprises a lipid;

b. characterizing the glycoaggregate using Diffusion Ordered Spectroscopy (DOSY) to determine a diffusion coefficient; and

c. comparing the diffusion coefficient to an optimal range of diffusion coefficients for a specific application to determine a quality of the glycoaggregate.

18, The method of claim 15, wherein the glycoaggregate is a micelle or vesicle.

17. The method of claim 15, wherein the glycopeptide is a drug or a pro-drug.

18. The method of claim 15, wherein the specific application is drug delivery.

19. The method of claim 15, wherein the glycopeptide is a glycosylated opioid peptide or lactomorphin.

20. The method of claim 15, wherein the lipid is a glycolipid according to any one of the following structures:


wherein R; is H, OH, Ο-β-D-Glucose, Ο-β-D-Galactose, or O-a-D-Giucose; wherein R2 is H or OH;

wherein th chain is accordin to any one of the followin formulas:


(1 :1) only only only wherien n is 6, 8, or 10.

21. The method of claim 15, wherein the lipid is according to any one of the following structures:


, A glycopeptide delivery system, comprising a giycoaggregate comprising:

a. a first co-surfactant comprising a glycopeptide; and

b. a second co-surfactant comprising a lipid;

wherein the first co-surfactant and the second co-surfactant aggregate to form said giycoaggregate, wherein the giycoaggregate has a diffusion coefficient determined using Diffusion Ordered Spectroscopy (DOSY),

, The delivery system of claim 22, wherein the giycoaggregate is a micelle or vesicle.

, The delivery system of claim 23, wherein the vesicle is a unilamellar vesicle or a multilamellar vesicle.

25. The delivery system of claim 22, wherein the giycopeptide is a drug or a prodrug.

26. The delivery system of claim 22, wherein the giycopeptide is a glycosylated opioid peptide or lactomorphin.

27. The delivery system of claim 22, wherein the lipid is a glycoiipid according to any one of the following structures:


wherein Ri is H, OH, Οβ-D-Glucose, Ο-β-D-Galactose, or O-a-D-Giucose; wherein R2 is H or OH;

wherein the chain is accordin to any one of the following formulas:


wherien n is 6, 8, or 10.

28. The delivery system of claim 22, wherein the lipid is according to any one of the following structures:

OOH


29. The delivery system of claim 22, wherein the delivery system is in a form of a nanoparticle or microemulsion.

30. The delivery system of claim 22, wherein the giycoaggregate has a diameter of about 5-10 nm.

31. The delivery system of claim 22, wherein the delivery system is configured to deliver the glycopeptide to a therapeutic site,

32. The delivery system of claim 22, wherein the giycoaggregate further comprising triglycerides.

33. The delivery system of claim 20, wherein the co-surfactants encapsulate the triglycerides.